
The East-West Bio Brief
Basil Lui
Biotech and beyond, from China, Asia and the West. Over half of global biotech licensing value comes from China, and the first signal often shows up in Chinese. Basil Lui (X: @basillui) and Ning turn primary sources into what matters for deals: a daily brief Tuesday to Sunday and a weekly roundup on Mondays. Beyond Biotech: health tech, diagnostics, AI drug discovery, lab automation, pet care and wearables. For BD teams, VCs and family offices. https://eastwestbiobrief.com Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Not investment advice.
Daily, Sun 15 Nov: Beijing adds 107 drugs, Europe says yes. Who wins?
Episode discussion: China adds 107 drugs to insurance list; Europe backs lung cancer treatments; FDA decision pending for ivonescimab
Speakers’ claims: Speakers report that China's National Healthcare Security Administration added 107 new drugs to its 2026 National Reimbursement Drug List, including a record 51 Class 1 innovative drugs. JW Therapeutics' CAR-T therapy and Novo Nordisk's insulin-semaglutide combination were highlighted as notable additions. In Europe, the EMA's CHMP backed Hansoh's aumolertinib and Innovent's sintilimab for lung cancer. Meanwhile, the FDA's decision on Akeso's ivonescimab remained pending as of the episode's recording. The speakers also discussed US regulatory restrictions on genetic data exports and their impact on clinical trials.
Daily, Sat 14 Nov: FDA decision day for ivonescimab, Akeso's lung cancer bispecific
Episode discussion: FDA decision day for Akeso's ivonescimab; BioNTech buys voucher; Intellia deadline set
Speakers’ claims: Basil Lui and AI co-host Ning discuss the November 14 FDA decision deadline for Akeso's ivonescimab, a PD1/VEGF bispecific licensed to Summit Therapeutics. They analyze the HARMONi trial results, noting progression-free survival benefits but missed statistical significance in overall survival, complicated by a trial population weighted 60% toward Asian patients. The episode contrasts Akeso's path with BioNTech's purchase of a priority review voucher and highlights Intellia's upcoming March 2027 deadline for its CRISPR therapy lonvo-z.
Daily, Thu 12 Nov: A Shanghai pill wins FDA approval, after China said yes first
Episode discussion: Abbisko's pimicotinib wins FDA approval; Akeso/Summit awaits ivonescimab decision; Windward Bio files US IPO
Speakers’ claims: The hosts discuss Abbisko's pimicotinib receiving FDA approval for tenosynovial giant cell tumor, noting the trial's significant Chinese patient inclusion under Project AUBIS. They highlight Merck KGaA's commercial rights and the milestone payment structure. The episode covers the upcoming November 14 FDA decision for Akeso and Summit's ivonescimab, focusing on the statistical significance of overall survival data. Additional topics include South Korea's new policy allowing travelers to import GLP-1 drugs, Windward Bio's US IPO filing, ImvivaBio's lupus CAR-T data, Shionogi's licensing deal in Singapore, and Neuralink's expanded PRIME 2 trial.
Daily, Sun 8 Nov: Akeso, pelacarsen, ziltivekimab and egg bioreactors
Episode discussion: Akeso drug enters priority review; ziltivekimab trials miss endpoints; Lifetech investment structure detailed
Speakers’ claims: Ning and Basil Lui discuss Akeso's ivonescimab entering China's priority review pathway, clarifying this is a regulatory step distinct from marketing approval. They analyze negative cardiovascular trial results for Novartis's HORIZON and Novo Nordisk's ZEUS, noting that biomarker reductions did not translate to clinical success. The hosts also cover Allist's AST-1001 receiving Phase 1 clearance, a proposed investment in Lifetech Scientific, and de-extinction tool companies. They emphasize that trial permissions and biomarker changes require patient outcome validation before assuming efficacy.